Junming Yie is an expert and in vitro biologist in metabolic disease, including diabetes, obesity, cardiovascular and muscular diseases, research, and drug discovery. Dr. Yie is currently a Senior Scientist in Amgen Inc. With over ten years of industrial research experience at Amgen In. and Pfizer Global R&D, Dr. Yie has worked on numerous early and late-stage projects in both biological and small molecule drug discovery. Dr. Yie has led projects for delivering one monoclonal antibody (in phase I clinical trial) and three small molecule candidates (one in phase I) and has been a key contributor for delivering three recombinant protein candidates (one in phase I) into development. Trained as a biochemist and a molecular and cell biologist, Dr. Yie earned his Ph.D. degree with distinction in biochemistry and molecular biophysics at the College of Physicians and Surgeons of Columbia University, NY, USA, under the supervision of Dr. Dimitris Thanos, and pursued his postdoctoral training in the laboratory of Dr. Bruce Spiegelmen in Dana-Farber Cancer Institute and Harvard Medical School. Dr. Yie published over a dozen of scientific papers in leading journals including Nature, Cell, Molecular Cell, PNAS, The EMBO Journal, and Molecular and Cellular Biology.
Biography Updated on 6 February 2012